APA (7th ed.) Citation

X, L., G, B., A, V., N, S., M, K., RS, H., . . . J, A. (2026). An oral, liver-restricted LXR inverse agonist for dyslipidemia: Preclinical development and phase 1 trial. Nature medicine, 32(3), 883. https://doi.org/10.1038/s41591-025-04169-6

Chicago Style (17th ed.) Citation

X, Li, et al. "An Oral, Liver-restricted LXR Inverse Agonist for Dyslipidemia: Preclinical Development and Phase 1 Trial." Nature Medicine 32, no. 3 (2026): 883. https://doi.org/10.1038/s41591-025-04169-6.

MLA (9th ed.) Citation

X, Li, et al. "An Oral, Liver-restricted LXR Inverse Agonist for Dyslipidemia: Preclinical Development and Phase 1 Trial." Nature Medicine, vol. 32, no. 3, 2026, p. 883, https://doi.org/10.1038/s41591-025-04169-6.